Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis
Open Access
- 1 March 2007
- journal article
- review article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 2 (1) , 27-31
Abstract
Exacerbations of chronic bronchitis (AECB) are a major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD), and their impact on public health is increasing. The new fluoroquinolones have an excellent spectrum providing cover for the most important respiratory pathogens, including atypical and "typical" pathogens. Not surprisingly, different guidelines have inserted these agents among the drugs of choice in the empirical therapy of AECB. The pharmacokinetic and dynamic properties of the new fluoroquinolones have a significant impact on their clinical and bacteriological efficacy. They cause a concentration-dependent killing with a sustained post-antibiotic effect. This review discusses the most recent data on the new fluoroquinolone prulifloxacin and critically analyses its activity and safety in the management of AECB.Keywords
This publication has 31 references indexed in Scilit:
- Pharmacologic characteristics of prulifloxacinPulmonary Pharmacology & Therapeutics, 2006
- Prulifloxacin: A new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitisPulmonary Pharmacology & Therapeutics, 2006
- Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosaInternational Journal of Antimicrobial Agents, 2005
- Penetration of Orally Administered Prulifloxacin Into Human Lung TissueClinical Pharmacokinetics, 2005
- Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophilsInternational Journal of Antimicrobial Agents, 2004
- PrulifloxacinDrugs, 2004
- Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infectionsExpert Opinion on Investigational Drugs, 2003
- In Vitro Activity of the Active Metabolite of Prulifloxacin (AF 3013) Compared with Six Other FluoroquinolonesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- In Vitro Antibacterial Activities of AF 3013, the Active Metabolite of Prulifloxacin, against Nosocomial and Community Italian IsolatesAntimicrobial Agents and Chemotherapy, 2001
- The Excess Cost of Acute Exacerbations of Chronic Bronchitis in Patients Aged 45 and Older in England and WalesValue in Health, 2001